Transplant recipients, accident victims, cancer patients and those undergoing major surgery all rely on safe and readily available supplies of blood and plasma.
As a global leader in the blood and plasma nucleic acid testing (NAT) screening market, Roche is bringing safety, reliability and efficiency to donor screening.
Nucleic Acid Testing (NAT) instruments, assays and reagents have been developped using high-performance real-time Polymerase Chain Reaction (PCR ) technology, a very sensitive technology to detect DNA and RNA molecules of infectious agents in an early stage of an infection, like HIV/HCV/HBV.
Easily integrated into pre- and post-analytic solutions they enable donor screening facilities to fully automate operations, boost throughput and achieve quicker turnaround times - leading to greater overall workflow efficiency.
Roche’s leading molecular solutions deliver predictable operational outcomes for laboratories and help to reduce the risk of disease transmission and adverse health effects in patients.